Lantus Solostar (Insulin Glargine)

Insulin glargine provides a steady, peak‑free level of insulin after subcutaneous injection by binding to insulin receptors on muscle and adipose tissue, promoting glucose uptake, and suppressing hepatic glucose production. Its altered amino‑acid sequence results in slow dissolution from the injection site, delivering basal insulin coverage for up to 24 hours.

The dose of Lantus Solostar is individualized; a qualified prescriber determines the starting amount and any subsequent adjustments based on the patient’s fasting glucose, HbA1c, body weight, renal function, and overall treatment plan. Dosing is typically expressed in units per day and administered once daily.

Safety data for insulin glargine in pregnancy and lactation are limited. It may be used when the expected benefit to the mother outweighs potential risks to the fetus or infant, and only under close medical supervision. Healthcare providers should evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lantus Solostar. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Lantus Solostar (insulin glargine) offers a 24‑hour, peak‑free basal insulin profile, similar to other long‑acting analogs such as insulin detemir or degludec. Compared with NPH insulin, it provides more predictable glucose control and a lower risk of nocturnal hypoglycemia, though individual response and cost considerations may influence the choice of therapy.

Lantus Solostar pens should be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen or shaken. Once in use, the pen may be kept at controlled room temperature (up to 30 °C) for up to 28 days, after which it should be discarded. Always keep the pen in its original packaging.

Lantus Solostar is a pre‑filled pen designed for subcutaneous injection. The pen is primed according to the manufacturer’s instructions, the dose is set by turning the dose selector, and the injection is given into the abdomen, thigh, or upper arm at a 90° angle. The dose is typically administered once daily at the same time each day.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis or angio‑edema. Patients should be educated to recognize early signs of hypoglycemia, monitor blood glucose regularly, and seek immediate medical attention if they experience symptoms of a severe allergic response.

Lantus Solostar is contraindicated in individuals with a known hypersensitivity to insulin glargine or any of the pen’s excipients. It should also be avoided in patients with severe hypoglycemia unawareness or those who cannot reliably monitor blood glucose. Use in patients with uncontrolled infections or acute illness should be carefully evaluated by a healthcare professional.